Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.3429 -0.0121 (-3.41%)
Streaming Delayed Price Updated: 11:49 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
From Cybin Inc.
Via Business Wire
Study Finds Using Social Media May Negatively Affect Youths’ Mental Health
Via Investor Brand Network
Study Finds That LSD Temporarily Reduces Binge Drinking in Rodents
Via Investor Brand Network
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City... 
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one... 
Via FinancialNewsMedia
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences
Via Investor Brand Network
Cybin to Participate in Upcoming Scientific and Investor Conferences
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe
Via Investor Brand Network
Hamilton Morris Confirmed as Keynote Speaker at Convergence Psychedelic Conference
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose
Via Investor Brand Network
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
From Cybin Inc.
Via Business Wire
Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development
Via Investor Brand Network
Study Finds Hepatitis C Drugs May Help Alleviate Symptoms of PTSD
Via Investor Brand Network
How Psychedelic Legalization, Decriminalization and Medicalization Differ
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research
Via Investor Brand Network
Exposures Censorship
Psychedelics May Make People Less Afraid of Death
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change... 
Via FinancialNewsMedia
Topics Supply Chain
Exposures Supply Chain
Study Highlights Need for Postnatal Depression Screening
Via Investor Brand Network
Study Shows Psilocybin Helps Alcoholics Reduce Drinking
Via Investor Brand Network
Exposures Product Safety
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD
Via Investor Brand Network
Topics Death
Exposures Death
Cybin Announces Final Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD
Via Investor Brand Network
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
How Psychedelics Startups Are Improving Their Resilience
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector
Via Investor Brand Network
Israeli Study identifies Bacterial Footprint in PTSD Sufferers
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.